X0609 4 2026-04-20 0002091349 First Tracks Biotherapeutics, Inc. TRAX 0001478916 Schmid John P. false 10770 WATERIDGE CIRCLE, SUITE 210 SAN DIEGO CA 92121 true false false false 0 Common Stock 31622 D Stock Option (right to buy) 6.58 2026-04-20 4 A 0 15000 0 A 2027-02-23 Common Stock 15000 15000 D Stock Option (right to buy) 28.03 2026-04-20 4 A 0 6000 0 A 2028-02-01 Common Stock 6000 6000 D Stock Option (right to buy) 18.43 2026-04-20 4 A 0 6000 0 A 2029-02-07 Common Stock 6000 6000 D Stock Option (right to buy) 4.43 2026-04-20 4 A 0 11000 0 A 2030-02-11 Common Stock 11000 11000 D Stock Option (right to buy) 7.95 2026-04-20 4 A 0 11000 0 A 2031-02-09 Common Stock 11000 11000 D Stock Option (right to buy) 8.14 2026-04-20 4 A 0 9200 0 A 2032-02-09 Common Stock 9200 9200 D Stock Option (right to buy) 6.22 2026-04-20 4 A 0 10600 0 A 2033-01-05 Common Stock 10600 10600 D Stock Option (right to buy) 5.67 2026-04-20 4 A 0 16510 0 A 2034-01-02 Common Stock 16510 16510 D Stock Option (right to buy) 3.97 2026-04-20 4 A 0 16510 0 A 2035-01-06 Common Stock 16510 16510 D Stock Option (right to buy) 11.75 2026-04-20 4 A 0 5500 0 A 2036-01-06 Common Stock 5500 5500 D Restricted Stock Unit 2026-04-20 4 A 0 6030 0 A Common Stock 6030 6030 D Restricted Stock Unit 2026-04-20 4 A 0 4000 0 A Common Stock 4000 4000 D Consists of shares of common stock received in connection with the spin-off of First Tracks Biotherapeutics, Inc. ("First Tracks") from AnaptysBio, Inc. ("AnaptysBio"). Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the "Separation Agreement"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire First Tracks shares of common stock in an amount determined in accordance with the Separation Agreement. The stock option is fully vested and exercisable. The stock option vests as to 1/12 of the total shares monthly commencing on February 6, 2026 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation Agreement, each outstanding RSU with respect to AnaptysBio shares of common stock was adjusted so that such RSU became an RSU with respect to First Tracks shares of common stock and an RSU with respect to AnaptysBio's shares of common stock. As a result, the Reporting Person acquired RSU s with respect to First Tracks shares of common stock in an amount determined in accordance with the Separation Agreement. The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2026 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date. The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2027 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date. /s/ Ajim Tamboli, Attorney-in-Fact 2026-04-22